Premenopausal breast cancer: Chemotherapy and endocrine therapy

Drugs

Volumn 62, Issue 14, 2002, Pages 2025-2038

  Sayer, Herbert G ^a   Kath, Roland ^b   Kliche, Kay Oliver ^a   Höffken, Klaus ^a  

^a Abteilung Haömatologie und Internistische Onkologie   (Germany)

^b Medizinische Klinik I   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; FORMESTANE; FULVESTRANT; GOSERELIN; LETROZOLE; MEDROXYPROGESTERONE ACETATE; MEGESTROL; METHOTREXATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIAZOLE DERIVATIVE; VOROZOLE;

ADJUVANT THERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; DRUG EFFECT; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; PREMENOPAUSE; PROGNOSIS; REVIEW; TUMOR LOCALIZATION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; PREMENOPAUSE; TAMOXIFEN;

EID: 0036400662     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262140-00003     Document Type: Review

References (77)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the world wide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80: 827-41
2. Szabo Cl, King MC. Inherited breast and ovarian cancer. Hum Mol Genet 1995; 4: 1811-7
3. Shiloh Y. Ataxia-telangiectasia, ATM, and genomic stability: Maintaining a delicate balance. Two international workshops on ataxia-telangiectasia, related disorders, and the ATM protein. Biochem Biophys Acta 1998; 1378: R11-8
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Projekt P-I Study. J Natl Cancer Inst 1998; 90: 1371-88
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352: 98-101
6. Veronesi U, Maisonneuve P, Costa A. et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 352: 93-7
7. Valero V, Buzdar A, Hortobagyi G. Neoadjuvant Chemotherapy in locally advanced breast cancer. Oncologist 1996; 1: 8-17
8. Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer 1994; 30A (7): 921-7
9. Buzdar AU, Singletary SE, Booser DJ, et al. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am 1995; 4 (4): 715-34
10. Adkins D, Brown K, Trinkaus R, et al. Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in Stage IIIB inflammatory breast cancer. J Clin Oncol 1999; 17: 2006-14
11. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy of the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-85
12. Mustacchi G, Latteier J, Milani S, et al. Tamoxifen versus surgery with tamoxifen as primary treatment for elderly patients with breast cancer: Combined data from the 'GREATA' and 'CRC' trials [abstract]. Proceedings of the American Society of Clinical Oncology 1998. Available from URL: http://www.asco.org [Accessed 2002 Sep 17]
13. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 1998; 351: 1451-67
14. National Institutes of Health Consensus Statements: Adjuvant Therapy for Breast Cancer [online]. Available from URL: http://consensus.nih.gov [Accessed 2000 Nov 1-3]
15. Pritchard K. Best types of endocrine treatments [abstract]. The Breast 2001; 10 Suppl. 1: S9
16. Fisher B, Digman J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999; 353: 1993-2000
17. Howell A, Downey S, Anderson E, et al. New endocrine therapies for breast cancer. Eur J Cancer 1996; 32A (4): 576-88
18. Osborne K, Zhao H, Fuqua SA, et al. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000; 18: 3172-86
19. Davidson N, O'Neill A, Vukov A, et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: An Eastern Cooperative Oncology Group Phase III Intergroup trial (E5188, INT-0101) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 67a
20. Jakesz R, Hausmaninger H, Samonigg H, et al. Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: Four year results of Austrian Breast Cancer Study group(ABCSG) Trail 5 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 67a
21. Boccardo F, Rubagotti A, Amoroso D, et al. for the Italian Breast Cancer Adjuvant Study Group. Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. J Clin Oncol 2000; 18: 2718-27
22. Jonat W on Behalf of the Zebra (Zoladex Early Breast Cancer Research Association) Trialist's Group. Zoladex (Goserelin) vs CMF as adjuvant therapy in pre/perimenopausal early (node positive) breast cancer: Preliminary efficacy, QOL and BMD results from the ZEBRA study. [abstract] Breast Cancer Res Treat 2000; 64: 13
23. Dowsett M, Stein RC, Coombes RC. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steriod Biochem Mol Biol 1992; 43: 155-9
24. Goldhirsch A, Glick JH, Gelber RD. et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001 Sep 15; 19 (18): 3817-27
25. Early Breast Cancer Trialists'Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998; 352: 930-42
26. Fisher B, Jeong JH, Dignam J, et al. Findings from recent national surgical adjuvant breast and bowel project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001; (30): 62-6
27. Goldhirsch A, Coates AS, Colleoni M, et al. Adjuvant chemoendokrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol 1998; 16: 1358-62
28. Rivkin SE. Green S, Lew D, et al. Adjuvant CMFVP versus Melphalan for operable breast cancer with positive axillary nodes: 23 Year results of a Southwest Oncology group study [Abstract]. Proc Am Soc Clin Oncol 1999; 18: 69a
29. Mansour EG, Gray R, Shatila AH, et al. Survival advantage of adjuvant chemotherapy in high risk node-negative breast cancer: Ten years analysis - An intergroup study. J Clin Oncol 1998; 16: 3486-92
30. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node positive breast cancer. N Engl J Med 1995; 332: 901-6
31. Hutchins L, Green S, Ravidin P, et al. CMF versus CAF with or without tamoxifen in high risk node negative breast cancer patients and a natural history of follow up study in node negative patients: First results of intergroup trial INT 0102. [abstract] Proc Am Soc Clin Oncol 1998; 17: 1a
32. Fisher B, Brown AM, Dimitrov NV, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15 [abstract]. J Clin Oncol 1990; 8: 1483-96
33. Levine MN, Bramvell VH, Pritchard KI. Randomized trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil on premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16: 2651-8
34. Mouridsen T, Andersen J, Anderson N, et al. Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin [abstract]. Proc Am Soc Clin Oncol 1999. 18: 68a
35. Gianni L, Zambetti M, Moliterni A. Cardiac sequelae in operable breast cancer patients after CMF ±doxorubicin (A) ± irradiation [abstract]. Proc Am Soc Clin Oncol 1999; 18: 68a
36. Budmann DR, Berry DA, Cirrincione CT, et al. Dose and dose-intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia Group B. J Natl Cancer Inst 1998; 90: 1205-11
37. Fumoleau P, Bremond A, Kerbrat P, et al. Better outcome of premenopausal node positive breast cancer patients treated with six cycles vs. three cycles of adjuvant chemotherapy: Eight year follow up results of FASG01 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 252
38. Henderson IC, Berry D, Demetri G, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer [abstract no. 390A]. Proc Am Soc Clin Oncol 1998; 17: 101a
39. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy. J Clin Oncol 1999; 17: 93-100
40. Rodenhuis S, Bonenbal M, Beex LVAM, et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes [abstract]. Proc Am Soc Clin Oncol 2000; 19: 286
41. Peters W, Rosner G, Vredenburgh J, et al. A prospective randomized comparison of two doses of combination alkyating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 [abstract]. Proc Am Soc Clin Oncol 1999; 18: 2
42. Hortobagyi GN, Buzclar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast cancer. J Natl Cancer Inst 2000; 92: 225-33
43. Bergh J. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC Therapy (The Scandinavian breast Cancer Study Group 9401) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 3
44. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82
45. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90: 1346-60
46. Bianco AR, De Laurentiis M, Carlomango C, et al. HER2 over-expression predicts adjuvant tamoxifen failure for early breast cancer: Complete data at 20 years of the naples gun randomised trial. [abstract] Proc Am Soc Clin Oncol 2000; 19: 289
47. Saez RA, Osborne CK. Hormonal treatment of advanced breast cancer. In: Kennedy BJ, editor. Breast cancer. Vol 1 of current clinical oncology. New York (NY): Alan R Liss, 1989:163-172
48. Santen RJ, Manni A, Harvey H, et al. Endocrine treatment of breast cancer in women. Endocr Rev 1990 May; 11 (2): 221-65
49. Klijn JGM. LH-RH agonists in the treatment of metastatic breast cancer: Ten years' experience. Recent Results Cancer Res 1992; 124: 75-90
50. Klijn JGM, Louk VA, Beex AM, et al. for the EORTC-Breast Cancer Cooperativ. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomised study. J Natl Cancer Inst 2000; 92 (11): 903-11
51. Klijn JGM, Blarney R, Boccarado F, et al. for the Combined Hormone Agents Trialists' Group and the European Organisation for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomised trials. J Clin Oncol 2001; 19: 343-53
52. Dowsett M, Doody D, Miall S, et al. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 1999; 56: 25-34
53. Celio L, Martinetti A, Ferrari L, et al. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: A comparative endocrine study. Anticancer Res 1999; 19: 2261-8
54. Stein RC, Dowsett M, Hedley A, et al. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62: 679-83
55. Lonning PE, Lien E. Mechanisms of action of endocrine treatment in breast cancer. Crit Rev Oncol Hematol 1995; 21: 158-93
56. Dombernowsky, P; Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Doubleblind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61
57. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998; 83 (69): 1142-52
58. Mouridsen HT, Gershanovich M, Monnier A, et al. Letrozole is superior to tamoxifen as first-line hormonal treatment of post-menopausal women with locally advanced or metastatic breast cancer (bc) [presented at the European Breast Cancer Conference 2000, abstract no. 489]. Ann Oncol 2000; 11 Suppl. 4: 155
59. Nabholtz JM, Budzar A, Pollak M, et al. for the Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a north American multicenter randomized trial. J Clin Oncol 2000; 18: 3758-67
60. Bonneterre J, Thürlimann B, Robertson JFR, et al. for the Arimidex Study Group. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18: 3748-57
61. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial. J Clin Oncol 2000; 18: 1399-411
62. Lonning E, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000; 18: 2234-44
63. Sledge GW, Hu P, Falkson G, et al. for the Eastern Cooperative Oncology Group. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An eastern cooperative oncology group study. J Clin Oncol 2000; 18: 262-6
64. A'Hern RP, Smith IE, Ebbs SR. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993; 67: 801-5
65. Verwei J, Clavel M, Chevalier P. Paclitaxel (taxol) and docetaxel (taxotere): Not simply two of a kind. Ann Oncol 1994; 5: 495-505
66. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-84
67. Johnson SA, Harper P, Hortobagyi GN, et al. Vinorelbine: An overview. Cancer Treat Rev 1996; 22: 127-42
68. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoetic stem cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-9
69. Sayer HG, Vogt T, Hoffmann K, et al. High response-rate of short duration with a double high-dose-chemotherapy regimen of doxorubicin/paclitaxel/cyclophos-phamide/thiotepa [ATCT] and peripheral blood progenitor cell support in patients with metastatic breast cancer [abstract]. Bone Marrow Transplant 2000; 26 Suppl. 1: S34
70. Falkson G, Gelman RS, Pandya KJ, et al. Eastern cooperative oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998; 16: 1669-76
71. Geels P, Eisenhauer E, Bezjak A, et al. Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2395-405
72. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48
73. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 127a
74. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol-19 Aredia Breast Cancer Study Group. J Clin Oncol 1998; 16: 2038-44
75. Diel IJ, Solomayer EF, Costa AD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63
76. Powles TJ, McCloskey E, Paterson AH, et al. Oral clondronate and reduction of loss in bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998; 90: 704-8
77. Hillner BE, Ingle JN, Berenson JR. et al. for the American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol 2000; 18: 1378-91